ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE

Post-LOE

enalapril maleate and hydrochlorothiazide

Bausch + Lomb

ANDAORALTABLET

Approved

Oct 2001

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE (enalapril maleate and hydrochlorothiazide) by Bausch + Lomb is mechanism of action enalapril, after hydrolysis to enalaprilat, inhibits angiotensin-converting enzyme (ace) in human subjects and animals. Approved for hypertension. First approved in 2001.

Drug data last refreshed 21h ago

Mechanism of Action

Mechanism of Action Enalapril, after hydrolysis to enalaprilat, inhibits angiotensin-converting enzyme (ACE) in human subjects and animals. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor substance, angiotensin II. Angiotensin II also stimulates…

Pharmacologic Class:

Thiazide Diuretic

Indications (1)

Worked on ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.